Majdi N Al-Hasan1, Jeanette E Eckel-Passow, Larry M Baddour. 1. Department of Medicine, Division of Infectious Diseases, University of Kentucky, Chandler Medical Center, 800 Rose Street, Room MN 672, Lexington, KY 40536, USA. majdi.alhasan@uky.edu
Abstract
BACKGROUND: Urinary tract infection (UTI) is common and bacteremia complicating this infection is frequently seen. There has been limited data published that characterize bacteremic UTI in a population-based setting over an extended period. We therefore examined the incidence rate, microbiology, outcome, and in vitro antimicrobial resistance trends of bacteremic UTI due to gram-negative bacilli in Olmsted County, Minnesota, from 1/1/1998 to 12/31/2007. METHODS: We used Kaplan-Meier method to estimate mortality rates, Cox proportional hazard regression to determine risk factors for mortality, and logistic regression to examine temporal changes in antimicrobial resistance rates. RESULTS: We identified 542 episodes of bacteremic gram-negative UTI among Olmsted County residents during the study period. The median age of patients was 71 years and 65.1% were females. The age-adjusted incidence rate per 100,000 person-years was 55.3 (95% confidence interval [CI]: 49.5-61.2) in females and 44.6 (95% CI: 38.1-51.1) in males. Escherichia coli was the most common pathogen (74.9%). The 28-day and 1-year all-cause mortality rates were 4.9% (95% CI: 3.0-6.8) and 15.6% (95% CI: 12.4-18.8), respectively. Older age was associated with higher mortality; community-acquired infection acquisition and E. coli UTI were both independently associated with lower mortality. During the study period, resistance rates increased linearly from 10% to 24% for trimethoprim-sulfamethoxazole and from 1% to 8% for ciprofloxacin. CONCLUSIONS: To our knowledge, this is the first population-based study of bacteremic gram-negative UTI. The linear trend of increasing antimicrobial resistance among gram-negative isolates should be considered when empiric therapy is selected. Copyright 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
BACKGROUND:Urinary tract infection (UTI) is common and bacteremia complicating this infection is frequently seen. There has been limited data published that characterize bacteremic UTI in a population-based setting over an extended period. We therefore examined the incidence rate, microbiology, outcome, and in vitro antimicrobial resistance trends of bacteremic UTI due to gram-negative bacilli in Olmsted County, Minnesota, from 1/1/1998 to 12/31/2007. METHODS: We used Kaplan-Meier method to estimate mortality rates, Cox proportional hazard regression to determine risk factors for mortality, and logistic regression to examine temporal changes in antimicrobial resistance rates. RESULTS: We identified 542 episodes of bacteremic gram-negative UTI among Olmsted County residents during the study period. The median age of patients was 71 years and 65.1% were females. The age-adjusted incidence rate per 100,000 person-years was 55.3 (95% confidence interval [CI]: 49.5-61.2) in females and 44.6 (95% CI: 38.1-51.1) in males. Escherichia coli was the most common pathogen (74.9%). The 28-day and 1-year all-cause mortality rates were 4.9% (95% CI: 3.0-6.8) and 15.6% (95% CI: 12.4-18.8), respectively. Older age was associated with higher mortality; community-acquired infection acquisition and E. coliUTI were both independently associated with lower mortality. During the study period, resistance rates increased linearly from 10% to 24% for trimethoprim-sulfamethoxazole and from 1% to 8% for ciprofloxacin. CONCLUSIONS: To our knowledge, this is the first population-based study of bacteremic gram-negative UTI. The linear trend of increasing antimicrobial resistance among gram-negative isolates should be considered when empiric therapy is selected. Copyright 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
Authors: Majdi N Al-Hasan; Avery N Nelson; Julie Ann Justo; Helmut Albrecht; Joseph Kohn; P Brandon Bookstaver Journal: Infection Date: 2018-02-07 Impact factor: 3.553
Authors: Patrick D Vigil; Travis J Wiles; Michael D Engstrom; Lev Prasov; Matthew A Mulvey; Harry L T Mobley Journal: Infect Immun Date: 2011-11-14 Impact factor: 3.441
Authors: Antonio Lalueza; Leticia Sanz-Trepiana; Noé Bermejo; Beatriz Yaiza; Alejandra Morales-Cartagena; María Espinosa; Rita García-Jiménez; Olga Jiménez-Rodríguez; Beatriz Ponce; David Lora; María Ángeles Orellana; Mario Fernández-Ruiz; Santiago Bermejo; José María Aguado Journal: Intern Emerg Med Date: 2016-11-18 Impact factor: 3.397
Authors: Bjoern F Kraemer; Robert A Campbell; Hansjörg Schwertz; Zechariah G Franks; Adriana Vieira de Abreu; Katharina Grundler; Benjamin T Kile; Bijaya K Dhakal; Matthew T Rondina; Walter H A Kahr; Matthew A Mulvey; Robert C Blaylock; Guy A Zimmerman; Andrew S Weyrich Journal: Blood Date: 2012-10-18 Impact factor: 22.113